A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis
NCT ID: NCT02759198
Last Updated: 2019-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
456 participants
INTERVENTIONAL
2016-05-02
2017-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee
NCT05362851
Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial
NCT04718649
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
NCT00689273
Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee
NCT03850587
A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee
NCT01873053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
YH23537
YH23537 750/1500/3000mg
YH23537
Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
Celebrex
Celecoxib 200mg
Celecoxib
Drug: Celecoxib 200mg
Placebo
YH23537 Placebo
YH23537 placebo
Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YH23537
Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
Celecoxib
Drug: Celecoxib 200mg
YH23537 placebo
Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women ≥ 40 years of age
* Patients with knee osteoarthritis at one or both knee by ACR
Exclusion Criteria
* Other exclusions applied
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yuhan Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoon Je Cho, M.D, Ph.D
Role: STUDY_CHAIR
Kyunghee University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KyungHee University Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YH23537-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.